HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 89/5/507    most recent expphysiol.2004.027789v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murphy, K.G. Articles by Bloom, S.R. Search for Related Content PubMed PubMed Citation Articles by Murphy, K.G. Articles by Bloom, S.R. Related Collections Hot Topic Reviews Neuroendocrinology/Endocrinology

Department of Metabolic Medicine, Imperial College Faculty of Medicine, Hammersmith Campus, Du Cane Road, London W12 ONN, UK

Obesity is one of the greatest threats to the health of the developed world. In order to design effective drugs to treat the alarming increase in obesity, it is essential to understand the physiology of normal appetite control and the pathophysiology of obesity. The hypothalamus interprets and integrates neural and humoral inputs to provide a coordinated feeding and energy expenditure response. Recent evidence suggests that certain gut hormones – ghrelin, polypeptide YY, pancreatic polypeptide, glucagon-like-peptide 1 and oxyntomodulin – have a physiological role in governing satiety via the hypothalamus. Gut hormone appetite-regulatory systems represent a potential target for the design of antiobesity drugs.

(Received 7 April 2004; accepted after revision 24 May 2004; first published online 7 June 2004)
Corresponding author S. R. Bloom, Department of Metabolic Medicine, Imperial College Faculty of Medicine, Hammersmith Campus, Du Cane Road, London W12 ONN, UK. Email: s.bloom{at}imperial.ac.uk

This article has been cited by other articles:

				S. Chearskul, E. Delbridge, A. Shulkes, J. Proietto, and A. Kriketos Effect of weight loss and ketosis on postprandial cholecystokinin and free fatty acid concentrations Am. J. Clinical Nutrition, May 1, 2008; 87(5): 1238 - 1246. [Abstract] [Full Text] [PDF]

				D. J. Paterson Celebrating 100 years of publishing discovery in physiology 1908 - 2008 Exp Physiol, January 1, 2008; 93(1): 1 - 15. [Full Text] [PDF]

				G. L. Rahardjo, X.-F. Huang, Y. Y. Tan, and C. Deng Decreased Plasma Peptide YY Accompanied by Elevated Peptide YY and Y2 Receptor Binding Densities in the Medulla Oblongata of Diet-Induced Obese Mice Endocrinology, October 1, 2007; 148(10): 4704 - 4710. [Abstract] [Full Text] [PDF]

				G. de Lartigue, R. Dimaline, A. Varro, and G. J. Dockray Cocaine- and Amphetamine-Regulated Transcript: Stimulation of Expression in Rat Vagal Afferent Neurons by Cholecystokinin and Suppression by Ghrelin J. Neurosci., March 14, 2007; 27(11): 2876 - 2882. [Abstract] [Full Text] [PDF]

				M. Fry, T. D. Hoyda, and A. V. Ferguson Making Sense of It: Roles of the Sensory Circumventricular Organs in Feeding and Regulation of Energy Homeostasis Experimental Biology and Medicine, January 1, 2007; 232(1): 14 - 26. [Abstract] [Full Text] [PDF]

				M. Shah, V. Simha, and A. Garg Long-Term Impact of Bariatric Surgery on Body Weight, Comorbidities, and Nutritional Status J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4223 - 4231. [Abstract] [Full Text] [PDF]

				I. R. Tough, N. D. Holliday, and H. M. Cox Y4 Receptors Mediate the Inhibitory Responses of Pancreatic Polypeptide in Human and Mouse Colon Mucosa J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 20 - 30. [Abstract] [Full Text] [PDF]

				S. Koda, Y. Date, N. Murakami, T. Shimbara, T. Hanada, K. Toshinai, A. Niijima, M. Furuya, N. Inomata, K. Osuye, et al. The Role of the Vagal Nerve in Peripheral PYY3-36-Induced Feeding Reduction in Rats Endocrinology, May 1, 2005; 146(5): 2369 - 2375. [Abstract] [Full Text] [PDF]